• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Magnetic resonance imaging-targeted biopsy noninferior to standard biopsy for prostate cancer screening

bySze Wah Samuel ChanandHarsh Shah
August 4, 2021
in Oncology, Public Health, Urology
Reading Time: 2 mins read
Computer-extracted MRI features help distinguish benign from malignant prostate lesions
Share on FacebookShare on TwitterShare on LinkedIn

1. Magnetic resonance imaging with targeted and standard biopsy was non-inferior for the detection of clinically significant cancers compared to standard biopsy only.

2. The detection of clinically insignificant cancers was less in the MRI group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Prostate cancer screening reduces prostate cancer mortality but has high rates of overdiagnosis of clinically insignificant prostate cancers. Magnetic resonance imaging (MRI) can visualize the suspicious lesions for biopsies and prevent biopsies where no visible lesions are seen. As such this study conducted a noninferiority trial between MRI-targeted biopsy with a standard biopsy and standard biopsy only for prostate screening. The primary outcome of non-inferiority was met where the percentage of clinically significant cancers was similar between the standard biopsy group and the MRI group. Furthermore, the MRI imaging group led to less clinically insignificant cancers biopsied compared to the standard biopsy group. The study was limited by the generalizability of the results as Sweden has a centralized radiologic and pathological assessment, which may not be the same in other healthcare systems. Nonetheless, the results from the study are significant as they demonstrated MRI-targeted and standard biopsy to be non-inferior to standard biopsy alone for prostate cancer screening.

Click here to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project

RELATED REPORTS

American Cancer Society recommends regular PSA-based screening for men at average and higher risk

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

In-Depth [randomized controlled trial]: This population-screening, randomized control trial invited 12,750 men in Stockholm County, Sweden. Men between 50 to 74 years of age and a previous prostate biopsy more than 60 days before the invitation were included in the study. Patients who were previously diagnosed with prostate cancer or a previous prostate cancer biopsy within 60 days of the invitation were excluded from the study. Of the initial 12,750 men invited for the study, 1,532 men had PSA levels of 3 ng per milliliter or higher and were randomized in a 2:3 ratio of either standard biopsy (standard group) or MRI and proceeding with standard and targeted biopsies (MRI group), respectively. In the intention-to-treat analysis, clinically significant cancer was found in 21% of the experimental group compared to 18% in the standard group (difference, 3 percentage points; 95% confidence interval [CI], -1 to 7%; p < 0.001 for noninferiority). Clinically insignificant cancers were detected in 4% of the experimental arm compared to 12% in the standard arm (difference, -8 percentage points; 95% CI, -11 to -5). If the standard biopsy was ignored in the MRI group, the experimental group would have not met the non-inferiority criterion at the 2.5% alpha level. Overall, the addition of MRI with standard and targeted biopsy has the potential to discriminate against clinically irrelevant lesions; however, costs and availability of MRIs will be key factors in the implementation of a cost-effective prostate cancer screening program.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: cancer screeningMRI-targeted biopsyprostate cancer
Previous Post

Active workstations may improve daily standing and step counts

Next Post

#VisualAbstract: Vitamin D3 supplementation may reduce disease recurrence in patients with stage II melanoma and low Breslow scores

RelatedReports

Collage on the PSA blood test: an engraved bladder and prostate, a capped blood tube, a balance scale and a blank calendar
2MM Trial Briefs

American Cancer Society recommends regular PSA-based screening for men at average and higher risk

November 12, 2026
A calendar, a specimen jar, and a brush are depicted alongside a microscopic view of cervical cells, indicating cervical cancer screening.
All Specialties

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

October 23, 2026
Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026
Lung cancer screening collage: a smiling white-haired man beside engraved lungs with a magnifying glass over the upper lobe
Oncology

Lung cancer screening models show variable performance across populations

June 29, 2026
Next Post
#VisualAbstract: Vitamin D3 supplementation may reduce disease recurrence in patients with stage II melanoma and low Breslow scores

#VisualAbstract: Vitamin D3 supplementation may reduce disease recurrence in patients with stage II melanoma and low Breslow scores

Downward trend in mortality rate for antineutrophil cytoplasmic autoantibody-associated vasculitis

Health care workers working on COVID-19 wards at increased risk for nosocomial SARS-CoV-2 infection

Disproportionately higher mortality from gastrointestinal congenital anomalies among lower income countries

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.